samedan logo
 
 
spacer
home > directory > eResearchTechnology, Inc. (eRT)
PHARMACEUTICAL INDUSTRY DIRECTORY

eResearchTechnology, Inc. (eRT)

eResearchTechnology, Inc. (eRT)

eResearchTechnology, Inc. (eRT)

Clinical Cardiac Safety and Data Management Solutions

eResearchTechnology, Inc. (eRT) is a global provider of cardiac safety services and electronic clinical data management solutions to the pharmaceutical, biotechnology and medical device industries. eRT is a leading centralized electrocardiographic (ECG) core laboratory providing cardiac safety technology and services for clinical development in Phase I-IV. eRT is also a leader in developing eClinical solutions focused on streamlining clinical trial conduct by enabling the collection, analysis and distribution of all clinical data.

Digital Collection, Analysis and Distribution of Cardiac Safety Data

1. An enhanced EXPeRT® 2 , eRT’s market leading analysis platform, is the heart of eRT’s operations providing scalable capacity and flexible workflow processing in a secure and validated environment

2. Flexible capacity and throughput to support the full-range of studies from single center to global, multi-center trials

3. eRT provides best-in-class 12-Lead Digital ECG devices for standard cardiac safety or Holter collection utilizing Mortara and GE Marquette ECG devices validated within EXPeRT

4. Full cardiac safety capabilities including best-practices digital collection, transmission and processing plus paper ECG processing and digital or paper rescue projects

5. SOP-driven, cross-functional Project Assurance methodology encompasses pre-study planning, set-up, monitoring and close-out activities which ensures effective study conduct and drives superior performance metrics

6. Regulatory compliance excellence

7. Global, 24/7 customer care, logistics and site support

8. Industry leaders for Thorough QTc/ECG Trials (TQT/TET), having completed significantly more than any other core lab

9. eRT Digital ECG Community provides on-demand data access in a secure web platform in addition to flexible reporting options and XML waveform viewing

10. eRT is an industry thought leader with experts available to consult on medical and regulatory issues related to cardiac safety, including protocol design and medical report writing

11. Global experience spanning 6 continents currently supporting over 15,000 investigation sites

12. eRT has established partnerships across the clinical services spectrum including partners in Japan and can facilitate assembly of best-in-class cross-functional solutions

13. eRT works with a balanced customer base serving the entire range of biopharmaceutical and emerging growth sponsors.

Clinical Data Solutions (eClinical)

eRT’s eClinical suite is a fully-supported, comprehensive and simple clinical data management platform that provides full functionality and services in support of clinical trials and directly integrates with EDC.

Key Applications

1. Clinical Information Portal (CIP)- eResearch Community      

2. Clinical Data Management System (CDMS)

3. Clinical Trial Management System (CTMS)

4. Adverse Event Reporting System (AERS)

5. Electronic Data Capture (EDC)

Key Features

1. One of the few that supports hybrid data entry (paper/EDC)

2. EDC has zero footprint and requires only Internet Explorer 6.0 or higher

3. eRT’s system supports both electronic query management as well as paper query management issuing DCFs

4. The system can generate paper CRFs to be used as templates for data entry for paper sites. The completed CRFs can also be printed from the system to PDF format and burned onto a CD for record retention at the site.

+44 (0) 1733 374800
eresearch@ert.com
www.ert.com
Pegasus House, Bakewell Road, Orton Southgate, Peterborough, Cambridgeshire PE2 6YS
 
Print this page
Send to a friend
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

PFIZER PRESENTS OVERALL SURVIVAL DATA FOR SUTENT™ VERSUS INTERFERON-ALFA

Chicago, 31 May 2008- Results from a landmark study have shown that sunitinib (SUTENT™) has demonstrated overall survival greater than two years in patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer.  This is the first time overall survival data representing more than two years has been achieved in the first line setting of mRCC, which is clinically meaningful and reflective of major advances in the treatment of kidney cancer. 
More info >>

 
©2000-2007 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement